Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health

Contributed by: Business Wire

Logo

Images

Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt

Business Wire embedded0

Tags

Oncology

Professional Services

Health

Finance

Research

Science

Pharmaceutical

AOP Orphan Pharmaceuticals GmbH

More Like This

Portrait: Dr. Rudolf Widmann | Member of the Board of Directors & Founder | AOP Health | Photocredit: AOP Health | Ospelt Photography

ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)

Professor Jean-Jacques Kiladjian, University of Paris, France Photo credit: AOP Health/Lorenz Paulus

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results

Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH

Professor Heinz Gisslinger, MedUni Vienna/Austria (Fotocredit: IntMedCom)

Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera to Be Presented at the American Society of Hematology (ASH) 65th Annual Meeting

AOP Health CEO Martin Steinhart (Copyright: AOP Health/Studio Koekart)

Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells

Rare Diseases: Collaboration is key. image: AdobeStock_1308212316

AOP Health on Rare Diseases: Information. Collaboration. Innovation.

Group photo management AOP Health and RHEACELL, from left to right: Dr. Christoph Ganss, Dr. Andreas Kluth, RHEACELL Dr. Rudolph Widmann, Dr. Günther Krumpl, Dr. Martin Steinhart, Bernhard Nachbaur, LL.M., AOP Health

RHEACELL and AOP Health: Strategic Partnership to Deliver Breakthrough Therapies for the “Butterfly Children’s Disease” and Chronic Venous Wounds

PR Newswire associated0

AOP Health Standardizes on Veeva Industry Cloud for Life Sciences Across All Business Areas